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A B S T R A C T
Background: Previous studies have revealed increased biological ageing amongst major depressive disorder
(MDD) patients, as assayed by shorter leukocyte telomere lengths (TL). Stressors such as childhood
maltreatment are more common amongst MDD patients, and it has been suggested that this might contribute
to shorter TL present amongst patients. However, to our knowledge, no study has yet tested for reverse
causality, i.e. whether a genetic predisposition to shorter TL might predispose to MDD or an earlier onset of
MDD.
Methods: This study used a Mendelian randomisation design to investigate if shortened TL might increase risk
for recurrent MDD in a relatively large UK sample (1628 MDD cases, 1140 controls). To achieve this, we used a
subset of our sample, for which TL data was available, to identify a suitable instrumental variable. We
performed single nucleotide polymorphism (SNP) genotyping on rs10936599, a SNP upstream of telomerase
RNA component (TERC), and rs2736100, a SNP within telomerase reverse transcriptase (hTERT), and
attempted to replicate ﬁndings which identiﬁed these SNPs as predictors of TL. After which, we performed
regressions to test if genetic risk for shortened TL increased risk for MDD, childhood-onset MDD or childhood/
adolescent-onset MDD.
Results: T-carriers of rs10936599 demonstrated shorter TL compared to CC-carriers (p≤0.05; 3% of variance
explained) and was subsequently used as our instrumental variable. We found that the T-allele of rs10936599
predicted increased risk for childhood-onset MDD relative to controls (p≤0.05), and increased risk for
childhood-onset MDD relative to adult-onset MDD cases (p≤0.001), but rs10936599 did not predict adult-
onset MDD risk.
Limitations: Limitations include a relatively small sample of early-onset cases, and the fact that age-of-onset
was ascertained by retrospective recall.
Conclusion: Genetic predisposition to advanced biological ageing, as assayed using rs10936599, predicted a
small, but signiﬁcant, increased risk for childhood-onset recurrent MDD. Genetic predisposition to advanced
biological ageing may be one factor driving previously reported associations (or lack of associations) between
shorter TL and MDD. Our results also suggest that the telomerase enzyme may act as a potentially important
drug target for the prevention of childhood-onset MDD, at least in a subset of cases. Future studies should
attempt to replicate our ﬁndings in a larger cohort.
1. Introduction
Telomeres are capping structures of tandem TTAGGG nucleotide
repeats found at the end of chromosomes (Eitan et al., 2014). During
each cell division, the ends of chromosomes shorten as part of a natural
consequence of replication (Aubert and Lansdorp, 2008). Telomeres
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function as sacriﬁcial, non-coding DNA buﬀers, which degrade instead
of inward, coding DNA regions (Allsopp et al., 1995). Eventually, in
cells which have undergone many divisions, telomeres become so short
that the coding DNA regions within the chromosome are no longer
protected, and their degradation triggers the end of that cell's ability to
replicate (Eitan et al., 2014). Telomere length (TL) subsequently acts as
marker for ‘cellular age’ or ‘biological age’; with shortened telomeres
representing older cells, and commonly, older individuals (Benetos
et al., 2001). However, unlike chronological age, biological ageing can
be moderated by environmental and genetic factors (e.g. Tyrka et al.,
2010, Codd et al., 2013), meaning two unrelated individuals of the
same chronological age, may not be the same age biologically.
Shortened leukocyte TL, relative to one's age, has been associated with
an increased risk to various diseases, generally poorer physical and
psychiatric health, and higher mortality (Simon et al., 2006; Fitzpatrick
et al., 2007; Kao et al., 2008; Yu et al., 2008; Okereke et al., 2012;
Lindqvist et al., 2015; Rode et al., 2015; Darrow et al., 2016).
Evidence suggests that an increased stress hormone response
(cortisol levels), oxidative stress, and immuno-inﬂammatory activation,
could be responsible for some of these inter-individual diﬀerences in
TL observed within the population (von Zglinicki, 2002; Jurk et al.,
2014; Gotlib et al., 2015). A disease which has been linked to all three
of these telomere-eroding factors, is major depressive disorder (MDD;
Cowen, 2002; Michel et al., 2012; Martin et al., 2015). Indeed, most
previous studies (e.g. Simon et al., 2006; Lung et al., 2007; Elvsåshagen
et al., 2011; Hoen et al., 2011; Garcia-Rizo et al., 2013; Verhoeven
et al., 2014) but not all (e.g. Wolkowitz et al., 2011; Teyssier et al.,
2012; Needham et al., 2015; Schaakxs et al., 2015), have revealed
shortened leukocyte TL amongst MDD patients with some studies
suggesting that shortened TLs may be observed most pervasively in
recurrent depressed cases only (e.g. Elvsåshagen et al., 2011).
Interestingly, a history of childhood maltreatment (a risk factor for
MDD) also predicts shortened TL in adulthood (Tyrka et al., 2010;
O'Donovan et al., 2011; Kananen et al., 2010; Shalev et al., 2014). This
has generated hypotheses which suggest that stress may simulta-
neously precipitate risk for MDD, and an advancement in telomere
shortening; contributing to the increased risk of comorbid ageing-
related disorders present amongst MDD patients; including cardiovas-
cular disease, obesity, and type-2 diabetes (Zhang et al., 2014).
Consequently, it's been hypothesized that negative environmental
factors, such as stress, are primarily responsible for shortened leuko-
cyte TL present amongst MDD patients. However, few reports have
considered the possibility of reverse causality, i.e. whether a predis-
position to advanced biological ageing (i.e. genetic factors) may also
predispose an individual to MDD.
A recent genome-wide association study (GWAS) revealed single
nucleotide polymorphisms (SNPs) predictive of relative TL; with the
two most signiﬁcant SNPs rs10936599 and rs2736100, located up-
stream or within the telomerase encoding genes telomerase RNA
component (TERC) and telomerase reverse transcriptase (hTERT),
respectively (Codd et al., 2013). These SNPs are hypothesized to aﬀect
the functionality of telomerase, an enzyme with the ability to reverse
telomere shortening, by adding TTAGGG sequences to the existing
telomere ends (Codd et al., 2013). Thus, SNPs coding for this enzyme
represent functionally discrete factors with pervasive eﬀects on long-
term TL maintenance. They also represent a means by which we can
test if inherent genetic factors inﬂuencing TL maintenance predict risk
for MDD.
Mendelian randomisation is an ‘instrumental variable analysis’ and
is the formal term used to describe a situation where we test whether
genetic factors (a ‘instrumental variable’) contributing to a biological
factor correlating with a disease (e.g. shortened telomere lengths)
directly predicts the disease itself (e.g. MDD; Sheehan et al., 2008;
Smith and Hermani, 2014). If it does, this would suggest that the
biological correlate may be involved in causing the disease, but if it
does not, it may indicate it is an eﬀect of having the disease, or that an
independent factor impacts upon both the biological correlate and the
disease.
Within this study we adopted a Mendelian randomisation design to
investigate whether a genetic predisposition to advanced biological
ageing (via rs10936599, rs2736100) predicted an increased risk of
recurrent MDD in a large UK sample. As MDD is generally an adult-
onset disorder (Kessler et al., 2001) and has been repeatedly associated
with biological ageing and risk for ageing-related disease (Zhang et al.,
2014), we also tested whether a genetic predisposition to advanced
biological ageing might shorten the time it takes for MDD to present
itself, i.e. increase risk for childhood (≤12 years old) or childhood/
adolescent-onset (≤17 years old) MDD. These earlier-onset time points
were chosen because they represent key, well-characterised, develop-
mental milestones and times during which there are increased rates of
cellular division, relative to adulthood. Therefore, phenotypes which
result from particular cell populations having a limited proliferative
potential (as a result of advanced biological ageing), may begin to
precipitate at these earlier time points.
To achieve our aims eﬀectively, we ﬁrst attempted to replicate Codd
and colleagues’ ﬁndings using relative TL data from an independent
cohort (and a subset of our genetic cohort), and to determine the best
genetic model and/or combination of the two SNPs (rs10936599 and
rs2736100) to use as our ‘instrumental variable’. Secondly, using a
large UK cohort of 1628 recurrent MDD cases and 1140 control
subjects, we tested whether the relative frequency of risk alleles for
shorter TL was greater amongst MDD cases, or early-onset MDD cases.
2. Methods
2.1. Subject information
Recurrent MDD cases were recruited from the UK component of
RADIANT, described previously (Lewis et al., 2010). Controls
(n=1140) were recruited from the Depression case-control study
(n=1040; Cohen-Woods et al., 2009), and from the South East
London Community Health Study (SELCoH, n=100; Hatch et al.,
2011). For a full break down, see Table 1.
2.2. Recurrent MDD cases
RADIANT is an umbrella term for three studies which sought to
understand genetic risk for MDD and factors aﬀecting response to
treatment; this comprised of the Depression Network (DeNT) study
(Farmer et al., 2004), the Depression Case-Control (DeCC) study
(Cohen-Woods et al., 2009) and the Genome-Based Therapeutic
Drugs for Depression (GENDEP) study (Uher et al., 2009). Within
these multi-centre clinical studies, we selected only those recruited
from the UK who had at least two episodes of major depression of at
least moderate severity, in order to create a homogeneous sample.
Diagnosis of MDD was ascertained using the Schedules for Clinical
Assessment in Neuropsychiatry (SCAN) interview in all three studies
Table 1
Descriptive statistics of case/control subjects within study; including total number of
participants, mean age at interview (with Standard Deviation) and numbers within each
gender.
Study N Age Males Females
DeCC cases 1248 47 (SD = 12.34) 380 868
GENDEP cases 83 46 (SD = 12.3) 29 54
DENT cases 297 46 (SD = 10.9) 71 226
Total Cases 1628 46.26 (SD =10.8) 480 1148
DeCC controls 1040 45 (SD = 9.8) 429 611
SELCoH controls 100 51 (SD = 16.9) 49 51
Total Controls 1140 46 (SD = 10.8) 481 669
Total 2768 46 (SD = 11.6) 958 1811
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(Wing et al., 1998), which was used to generate International
Classiﬁcation of Diseases, 10th edition (ICD-10; World Health
Organisation, 1992), and the Diagnostic and Statistical Manual of
Mental Disorders, revised third edition (DSM-III-R; American
Psychiatric Association, 1987), diagnoses. People who had ever fulﬁlled
criteria of intravenous substance dependence, substance-induced mood
disorder, schizophrenia or bipolar disorder were excluded from all
three studies. Information on the age of onset of MDD and number of
episodes were obtained by questionnaires and clinical interviews. In
total there were 206 childhood-onset cases, and 518 childhood/
adolescent-onset cases. All participants were of White European
ancestry.
2.3. Control subjects
The majority of controls were derived from those recruited as part
of DeCC, a subset of RADIANT. Subjects were screened for lifetime
absence of any psychiatric disorder using a modiﬁed version of the Past
History Schedule (McGuﬃn et al., 1986). Participants were excluded if
they, or a ﬁrst-degree relative, ever fulﬁlled the criteria for MDD or any
other psychiatric disorder. We also included a subset of SELCoH
subjects as controls, genotyped within the current study. SELCoH is
a population study in London, UK, investigating community health
(Hatch et al., 2011). It's an on-going study, in which phenotypic
information has been collected over three phases over an eight-year
period, with blood being collected in the third phase. Control subjects
were identiﬁed as those with no depression symptoms on any of the
three assessment phases, as measured using the Clinical Interview
Schedule-Revised (Lewis et al., 1992), and no previous history of a
depressive disorder as ascertained using a self-report questionnaire.
77% of the SELCoH controls showed no other psychiatric symptoms
outside of MDD in all three phases (neurotic disorders, anxiety
disorders, obsessive compulsive disorder, phobias, panic disorder);
with 93% having no psychiatric symptoms at the time of blood
collection. Therefore, 97.8% of our total control group contained
individuals with no lifetime history of any psychiatric symptoms. All
participants were of White European ancestry.
2.4. Ethics
The SELCoH study received approval from the King's College
London research ethics committee, reference PNM/12/13–152. The
RADIANT studies were approved by the Joint South London and
Maudsley NHS Trust Institute of Psychiatry Research Ethics
Committee. Informed written consent was obtained from all the
participants at the time of sample collection.
2.5. Validating our instrumental variable
In order to perform Mendelian randomisation we ﬁrst attempted to
validate whether rs10936599 or rs2736100 predicted relative TL in our
sample. We used TL data that was collected as part of a diﬀerent study
(n=180; Vincent et al., under submission). Brieﬂy, subjects in this
subsample were chosen based on: (i) availability of leukocyte DNA
samples, (ii) participants being White and from the UK (due to
population diﬀerences in TL), (iii) availability of information on
depressive disorder case/control status and childhood maltreatment.
We attempted to validate our instrumental variables using data
generated from all 180 subjects, with 125 of these subjects (SELCoH
controls and recurrent MDD patients from DeCC only) also included in
our main analysis investigating genetic risk to biological ageing and its
relationship to recurrent MDD.
2.6. Relative telomere length in SELCoH and DeCC subset
Brieﬂy, TL was quantiﬁed in our sample subset using the output
from two separate quantitative real-time polymerase chain reactions
(qPCRs). The ﬁrst qPCR assays the telomere repeat region (TTAGGG),
and the second qPCR assays a single copy gene (albumin). The ratio
between the telomere repeat region and the single copy gene was
calculated to determine relative TL. Relative TL was then log trans-
formed and adjusted for the confounding eﬀects of age, gender and
study by taking the standardized residuals. Previous work on this data
set found no confounding eﬀects of body mass index, smoking habits,
antidepressant use, drug dependency, drug use, other medication use,
or comorbid diseases, on relative telomere length (Vincent et al., under
submission). The output was used to test the eﬀect of SNPs on adjusted
log(relative TL). For full details, see Supplementary Information.
2.7. SNP genotyping in the SELCoH sample
Genotyping of 155 subjects within SELCoH was performed within
the current study. Genomic DNA within SELCoH was extracted from
blood using standard extraction methods (Freeman et al., 2003). One
negative (no template) control sample for each gene (2.6 μl RNase-free
water) was included to conﬁrm absence of nucleic acid contamination.
SNP genotyping was assayed using a Taqman SNP genotyping assay
(Thermo Fisher Scientiﬁc, Massachusetts, United States). Each reac-
tion mix consisted of 2.5 μL 2x Taqman Genotyping Mastermix
(Thermo Fisher Scientiﬁc), 0.125 μL 40x Taqman Genotyping Assay
Mix (Thermo Fisher Scientiﬁc), and 10 ng DNA. rs10936599 (Cat. #
4351379) and rs2736100 (Cat. # 4351379) SNP genotyping assays
contained allele-speciﬁc primers which were tagged with either FAM or
VIC labelled probes, Table 2. The diﬀerences in ﬂuorescence emission
allows for both alleles to be detected simultaneously within a single
well.
The polymerase chain reaction was performed using the ABI Prism
7900HT Sequence Detection System (Applied Biosystems,
Massachusetts, USA) and an allelic discrimination analysis using SDS
2.3 (Applied Biosystems) was used to determine genotypes within each
of the 155 samples included on a 384-well plate, following the standard
manufacturer's protocol.
2.8. Already available genotype data from RADIANT
SNP data from RADIANT was already available. Genomic DNA
within RADIANT was extracted from bloods and cheek swabs collected
as described previously (Freeman et al., 2003). DNA samples were then
sent to the Centre National de Genotypage (Evry Cedex, France) and
were genotyped using the Illumina Human610-Quad bead chip
(Illumina, Inc., San Diego, CA, USA). Genotype data for single
Table 2
Details of rs10936599 and rs2736100 including their location, the genomic region
assayed by VIC and FAM probes, and minor and major allele frequencies.
rs10936599 (TERC)
Location Chr.3;169492101
Context
Sequence
(VIC/FAM)
ATATCAAAATGCAGTATTCGCACCA[C/T]
TGTGAGCACCTTTTAGAGAGACTGA
Minor Allele
Frequency
T = 0.27
Major Allele
Frequency
C = 0.73
rs2736100 (hTERT)
Location Chr.5;1286516
Context
Sequence
(VIC/FAM)
GAAAAGCAGGGCGGGGGCAAAGCTA[A/C]
AGAAACACTCAACACGGAAAACAAT
Minor Allele
Frequency
A = 0.47
Major Allele
Frequency
C = 0.53
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nucleotide polymorphisms (SNPs) under investigation in this study
were extracted using PLINK (Purcell et al., 2007).
2.9. Statistical analysis
(i) Validation of our instrumental variable: First, we performed a
Chi-Square test to ensure the 180 subjects with TL data were
representative of the population, and that the relative frequency of
alleles did not deviate from Hardy-Weinberg equilibrium.
Subsequently, we performed univariate linear regressions to
determine the eﬀect of rs10936599 and rs2736100 on adjusted
log(relative TL) as part of additive, dominant and recessive
models.
(ii) Case-control comparison: Again, we tested whether the relative
frequency of alleles in this larger cohort deviated from Hardy-
Weinberg equilibrium. We then performed a generalized linear
model with the binomial distribution and speciﬁed identity link
function (Wacholder 1986) in order to establish risk diﬀerence
(RD), as previously done in Fisher et al. (2013). We included
MDD case/control status as the outcome variable, with SNP(s)
predicting telomere length, and gender, included as independent
factors.
(iii) Age of onset comparison: We tested whether SNP(s) predicting TL
may predict early onset MDD. We tested the eﬀect of SNP(s) on
childhood-onset MDD (≤12 years old), child/adolescent-onset
MDD (≤17 years old) and also for comparison, adult-onset
MDD (≥18 years old). To achieve this we performed the same
generalized linear model as above but with a subset of cases based
on age-of-onset, and all controls included. We also compared
early-onset cases with adult-onset MDD cases. The false discovery
rate (FDR) method of multiple testing correction was used to
determine true associations in analyses (ii) and (iii), with a q value
threshold of q < 0.05.
3. Results
3.1. Validation of instrumental variable
There was a 100% call rate for both rs10936599 and rs2736100 for
all 155 DNA samples which underwent SNP genotyping, and there was
no ampliﬁcation in the negative control. In the total sample of 180, for
which there was corresponding TL data, neither rs10936599 [CC=98,
CT=74, TT=8; χ2=1.67, p=0.196], or rs2736100 [AA=44, AC=92,
CC=44; χ2=0.09, p=0.764], deviated from Hardy-Weinberg equili-
brium.
Subsequently, we used a series of univariate linear regressions to
determine which allelic combination explained the greatest variance in
adjusted log(relative TL), and thus which allelic combination should be
utilized as our ‘instrumental variable’. In the case of rs2736100, the A-
allele represents the risk SNP for shortened TL, in the case of
rs10936599, the T-allele represents the risk SNP for shortened TL
(Codd et al., 2013). Our results are summarized in Table 3. We found
that the presence/absence of the T-allele (rs10936599; dominant
model) was the strongest predictor of adjusted log(relative TL),
explaining 3% of the variance, Fig. 1.
3.2. rs10936599 as a predictor of recurrent MDD and age of onset
comparison
In addition to utilizing data from our subset with corresponding TL
data, we also used previously collected genotype data from RADIANT
for subsequent analyses. To ensure this combined UK sample remained
representative of the general population, we again checked if
rs10936599 fell within Hardy-Weinberg equilibrium. We found no
deviation from Hardy-Weinberg equilibrium in the total sample
(CC=1577; CT=1012; TT=179; χ2=0.900; p=0.343).
Generalized linear models revealed no eﬀect of rs10936599 geno-
type (TT/CT versus CC) on general MDD case/control status
(p=0.700), or adult-onset MDD (p=0.106), Table 4. To investigate if
rs10936599 might predict earlier onset MDD, we investigated whether
rs10936599 predicted childhood-onset MDD (≤12 years old) as part of
a case-control comparison, and as part of a childhood-onset MDD case
versus adult onset (≥18 years old) MDD within-case comparison.
Similarly, we did the same analyses for childhood + adolescent onset
MDD cases (≤17 years old). rs10936599 signiﬁcantly predicted child-
hood onset MDD both as part of a case-control comparison (p=0.012;
Fig. 2), and as part of a childhood-onset versus adult-onset MDD
within-case comparison (p=0.001; Fig. 2). To a lesser extent,
rs10936599 also predicted childhood/adolescent-onset MDD relative
to adult-onset MDD cases (p=0.02; Fig. 2). The FDR method of
multiple testing correction was used, and conﬁrmed that all three
eﬀects remained signiﬁcant at a q threshold of q < 0.05.
4. Discussion
The aim of this study was to investigate the eﬀect of rs10936599
Table 3
Results from univariate linear regressions investigating the allelic combinations of
rs2736100 and rs10936599 as predictors of adjusted log(relative TL) in 180 UK subjects.
rs10936599 genotype was found to significantly predict adjusted log(relative TL) as part
of both an additive and dominant model. The dominant model was the most significant
predictor and explained the most variance, so was selected as our ‘instrumental variable’.
SNP Model Tested F P value Variance
Explained
rs2736100 Additive (CC=0,
AC=1, AA=2)
2.960E-04 0.986 0.000
rs2736100 Dominant (CC=0,
AC/AA=1)
0.370 0.544 0.002
rs2736100 Recessive (AA=0,
AC/CC=1)
0.416 0.520 0.002
rs10936599 Additive (CC=0,
TC=1, TT=2)
4.884 0.028 0.027
rs10936599 Dominant (CC=0,
TC/TT=1)
5.237 0.023* 0.029
rs10936599 Recessive (TT=0,
TC/CC=1)
1.513 0.220 0.009
rs2736100 +
rs10936599
Additive (CC=0,
AC=1, AA=2; CC=0,
TC=1, TT=2)
1.949 0.164 0.011
Fig. 1. A plot showing the eﬀect of rs10936599 on adjusted log(relative TL). Genotypes
with one or two risk alleles (TC/TT) are signiﬁcantly associated with shorter adjusted
telomere length relative to genotypes with no risk allele (C/C), p < 0.05.
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and rs2736100 on leukocyte TL and subsequently the impact of genetic
risk for shorter TL on risk for recurrent MDD status, childhood-onset
recurrent MDD, and childhood/adolescent-onset recurrent MDD. First,
our results revealed that the T-allele of rs10936599 was the best
predictor of shortened TL in a subset of our sample, Fig. 1, Table 3. The
T-allele was the most signiﬁcant predictor of shortened telomere length
in an independent GWAS consisting of the largest sample to-date
(Codd et al., 2013), and thus, we felt conﬁdent in using rs10936599 as
our instrumental variable predicting increased risk for biological
ageing.
We subsequently performed Mendelian randomisation to probe if
genetic predisposition to advanced biological ageing (T-carriers of
rs10936599) predicted risk for recurrent MDD. rs10936599 did not
predict risk for recurrent MDD in our general case-control comparison,
nor to adult-onset recurrent MDD. However, our study revealed that a
genetic predisposition to advanced biological ageing may increase risk
for early-onset MDD. We found a small but statistically signiﬁcant
increased risk to childhood-onset recurrent MDD relative to controls,
and a signiﬁcant increased relative risk to recurrent childhood-onset
MDD relative to recurrent adult-onset cases amongst T-allele carriers
of rs10936599, Fig. 2, Table 4. To a lesser extent we also found an
increased risk for recurrent childhood/adolescent-onset MDD relative
to recurrent adult-onset MDD, Fig. 2, Table 4.
Childhood and adolescent MDD are far more rare than adult-onset
MDD, with a prevalence in the general population of less than 1%
(Kessler et al., 2001); with much lower rates of childhood MDD (before
puberty) than adolescent-onset MDD (Green et al., 2005).
Consequently, independent genetic factors may impinge upon risk for
early-onset MDD relative to adult-onset MDD, which has been
supported by recent research (Power et al., 2016). Our results suggest
that a genetic predisposition to advanced biological ageing may shorten
the time it takes for the disease to present itself, and therefore lowers
the age of onset of recurrent MDD, evoking childhood-onset symptoms.
Due to the fact that rs10936599 lies upstream of the gene encoding the
telomerase enzyme, a discrete and modiﬁable biological factor, our
results suggest that increasing the activity of telomerase may hinder the
early onset of childhood MDD amongst those at high risk, e.g. those
with a familial risk of MDD and carriers of the T-allele of rs10936599.
Previous research suggests this could be achieved pharmacologically
(e.g. via alterations to the immune system) or through changes to
lifestyle factors (Akiyama et al., 2002; Boccardi et al., 2016).
In order to interpret the validity of our conclusions, it is important
to consider whether we may have violated any of the assumptions
surrounding Mendelian randomisation. The ﬁrst assumption states
that the genotype in question is associated with the phenotype, or
biological correlate of interest (Glymour et al., 2012). This assumption
Table 4
The effects of carrying the T-allele of rs10936599 on risk for recurrent MDD, childhood-onset recurrent MDD, or childhood/adolescent onset recurrent MDD. Results include the sex
adjusted relative risk differences, p-values, confidence intervals and FDR-corrected q-values. * indicate significant effects (q < 0.05).
rs10936599 eﬀect on MDD Adjusted Relative Risk Diﬀerence P value 95% Conﬁdence Intervals Q-value
All MDD Cases v Controls −0.007 0.700 −0.044 0.029 0.700
Adult onset MDD v Controls −0.356 0.106 −0.079 0.007 0.159
Childhood/adolescent onset MDD v Controls 0.023 0.296 −0.021 0.068 0.355
Childhood onset MDD v Controls 0.048 0.012* 0.011 0.087 0.036
Childhood/adolescent onset MDD v Adult onset MDD 0.060 0.020* 0.009 0.110 0.040
Childhood onset MDD v Adult onset MDD Cases 0.082 0.001* 0.035 0.128 0.006
Fig. 2. The relative frequency (%) of CC versus TC/TT carriers for rs10936599 amongst: (A) controls and childhood-onset (C-O) recurrent MDD cases; (B) adult-onset (A-O) recurrent
MDD cases and childhood-onset (C-O) recurrent MDD cases; (C) adult-onset (A-O) recurrent MDD cases and childhood/adolescent-onset (C/Ad-O) recurrent MDD cases. Absolute
numbers in each group are shown on top of each bar. There were signiﬁcantly higher numbers of T-allele carriers amongst childhood-onset or childhood/adolescent recurrent MDD
cases in all groups (p < 0.05).
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was met, since we found that the rs10936599 genotype is signiﬁcantly
associated with shorter TL. Secondly, it is assumed that there are no
unmeasured common causes of rs10936599 genotype and recurrent
MDD (Glymour et al., 2012). Since no other link was found to inﬂuence
both the rs10936599 genotype and childhood-onset MDD, the second
assumption was also met in this study. The ﬁnal assumption of
Mendelian randomisation is that the instrumental variable
(rs10936599 polymorphism) directly aﬀects the outcome (childhood
onset MDD) only via the exposure of interest (telomere shortening;
Glymour et al., 2012). Since the instrumental variable used in our
analysis was reliably associated with telomere shortening in previous
studies as well as our own, and has functionally plausible eﬀects on
telomerase, an enzyme which quite speciﬁcally aﬀects cellular ageing,
this assumption was met in our study. Nonetheless, it was previously
argued that the second and third assumptions are not possible to
describe empirically (Martens et al., 2006). Furthermore, until under-
standing the fundamental biochemical mechanism relating
rs10936599 genotype to childhood-onset MDD has been achieved,
we need to accept the possibility that both second and third assump-
tions might be violated (Hung et al., 2014).
The main limitations of the current study stem from the relatively
small number of childhood-onset cases, and the small-moderate
predictive power of our instrumental variable. Further work will be
needed to replicate our work in a larger sample to form ﬁrmer
conclusions, using a more powerful instrumental variable (e.g. a
polygenic risk score), as rs10936599 only explained 3% of the variance
in TL in our sample. However, within the current study we do beneﬁt
from a homogenous sample set, both in terms of population structure
and recurrent MDD diagnosis. Another limitation is the absence of data
on maltreatment and body mass index during childhood, which may
have interacted with our genetic factors to moderate risk for MDD. This
would best be considered in future studies with a longitudinal study
design; allowing for developmentally-sensitive gene-environment in-
teractions to be tested.
To conclude, our study provides evidence that a genetic predisposi-
tion to advanced biological ageing may increase risk for early-onset
MDD. In practice, it might be beneﬁcial for those who are genetically
vulnerable to advanced biological ageing (T-carriers of rs10936599),
with a family history of MDD, to actively engage in behaviours which
protect from telomere erosion, such as a healthy diet, physical activity,
and the avoidance of stress (Simon et al., 2006; Richards et al., 2007;
Werner et al., 2009). Future studies should further characterise the
functional eﬀect rs10936599 has on leukocyte telomerase activity,
especially amongst early-onset MDD cases, and whether or not the
telomerase enzyme represents an important drug target for the
prevention of early-onset MDD. Further work will also be needed to
understand the impact of advanced biological ageing on the developing
brain and which neural mechanisms moderate risk for childhood-onset
MDD.
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